IPO vs. THNR ETF Comparison
Comparison of Renaissance IPO ETF (IPO) to Amplify Weight Loss Drug & Treatment ETF (THNR)
IPO
Renaissance IPO ETF
IPO Description
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Renaissance IPO Index (the "index"). The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index, the Renaissance IPO Index. The remaining 20% may be used to purchase securities not in the index that are an appropriate substitute for certain securities in the index in order to track the index. The index is comprised of common stocks, American Depositary Receipts ("ADRs"), real estate investment trusts ("REITS") and master limited partnerships ("MLPs"). The fund is non-diversified.
Grade (RS Rating)
Last Trade
$45.56
Average Daily Volume
29,456
17
THNR
Amplify Weight Loss Drug & Treatment ETF
THNR Description
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists (glucagon-like peptide) seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.Grade (RS Rating)
Last Trade
$23.15
Average Daily Volume
2,584
15
Performance
| Period | IPO | THNR |
|---|---|---|
| 30 Days | 2.13% | -11.31% |
| 60 Days | 6.15% | -15.54% |
| 90 Days | 8.19% | -17.09% |
| 12 Months | 37.53% |
0 Overlapping Holdings
| Symbol | Grade | Weight in IPO | Weight in THNR | Overlap |
|---|
IPO: Top Represented Industries & Keywords
THNR: Top Represented Industries & Keywords
Compare ETFs
